New Regulatory Framework for Drug Approvals - SFDA · 2020. 3. 23. · 2.0 Licensing department 15 July 2008 Published for comments 3.0 Licensing department 19 January 2009 Revised

Version 6.0

This document is a draft published for comments and suggestions

purposes. It is, therefore, subject to alteration and modification and may not

be referred to as SFDA’s document until approved by SFDA

Date of publication 15 July 2008

Date of implementation 5 July 2009

2

Regulatory Framework for

Drugs Approval

Version 6.0

Saudi Food & Drug Authority

Drug Sector

Please send your comments or suggestions before

January 17, 2020 to:

[email protected]

Please visit SFDA’s website at

http://www.sfda.gov.sa/en/drug/drug_reg/Pages/default.aspx

for the latest update

mailto:[email protected]

http://www.sfda.gov.sa/en/drug/drug_reg/Pages/default.aspx

3

Saudi Food and Drug Authority

Vision and Mission

Vision

To be a leading international science-based regulator to protect and

promote public health

Mission

Protecting the community through regulations and effective controls to

ensure the safety of food, drugs, medical devices, cosmetics, pesticides

and feed

4

Document Control

Version Author Date Comments

1.0 Licensing department 15 March 2008 Initial draft for internal

consultation

2.0 Licensing department 15 July 2008 Published for comments

3.0 Licensing department 19 January 2009 Revised draft

4.0 Licensing department 5 July 2009 Final version posted

5.0 Regulatory Affairs 16 March 2014 Update

6.0 Executive Directorate

of Regulatory Affairs

17 December 2019 Update and published for comment

purposes

(Next page shows the updated

details)

5

What is the main updates in version no. 6?

Section Description of change

Glossary New definitions for New (innovative) and Generic products.

Add definitions for biotechnology products, blood products,

wave and medicinal gases

Update the definition of biologics

Add Stringent Regulatory Authorities (SRA) for veterinary

products

3. New Marketing

Authorization Application

Update the submission process

Responding period for the business validation inquiries is 30

working days

Add cases when the registration requests will be rejected

Total performance target for Herbal & health products reduced

from 155 to 95 working days

Update performance targets for veterinary products

4. Variation of Marketing

Authorization



working days

Add cases when the variation requests will be rejected

Total performance targets reduced as the following:

o Type 1A: from 60 to 30 working days

o Type 1B: from 120 to 60 working days

o Type 2: from 145 to 100 working days

5. Renewal of Marketing

Authorization



working days

Add cases when the renewal requests will be rejected

The renewal process is shorter and total performance target

reduced from 70 to 40 working days

Performance Targets The performance targets for all applications stated in details for all

steps:

Section 3.5: for Registration Request

Section 4.5: for Variation Request

Section 5.4: for Renewal Request

6

Table of Contents:

Acronyms and abbreviations .................................................................................... 8

Glossary ................................................................................................................... 9

1. Introduction .................................................................................................... 12

2. Scope: ............................................................................................................. 12

3. New marketing authorization application ....................................................... 13

3.1. Submission .................................................................................................. 13

3.1.1. Online submission ................................................................................... 13

3.1.2. Validation ................................................................................................ 13

3.1.2.1. Technical validation ................................................................................ 13

3.1.2.2. Business validation .................................................................................. 13

3.2. Assessment .................................................................................................. 14

3.2.1. Evaluation / inspection ............................................................................ 14

3.2.2. Testing ..................................................................................................... 15

3.3. Pricing ......................................................................................................... 16

3.4. Product licensing ......................................................................................... 16

3.5. Registration performance targets ................................................................ 18

3.5.1. Regular pathway ...................................................................................... 18

3.5.2. Priority review pathway .......................................................................... 19

3.5.3. Verification & abridged pathway ............................................................ 19

4. Variation of marketing authorization ............................................................. 20

4.1. Submission .................................................................................................. 20


4.1.2. Business validation .................................................................................. 21

4.2. Assessment .................................................................................................. 21

4.2.1. Evaluation / inspection ............................................................................ 21

4.3. Pricing ......................................................................................................... 22


4.5. Variation performance targets ..................................................................... 24

5. Renewal of marketing authorization ............................................................... 25

5.1. Submission .................................................................................................. 25

7


5.1.2. Business validation .................................................................................. 25

5.2. Pricing ......................................................................................................... 26


5.4. Renewal performance targets ...................................................................... 27

6. Appendix ........................................................................................................ 28

6.1. Application forms ....................................................................................... 28

8

Acronyms and Abbreviations

API Active Pharmaceutical Ingredients

ATC Anatomical Therapeutic Chemical Classification System

ATC vet Anatomical Therapeutic Chemical Classification System for veterinary

products

BSE Bovine spongiform encephalopathy

CEO Chief Executive Officer

COO Country of Origin

CPP Certificate of Pharmaceutical Product

CTD Common Technical Document

EMA European Medicines Agency

KSA Kingdom of Saudi Arabia

MA Marketing Authorization

MAA Marketing Authorization Application

MHRA Medicines and Healthcare products Regulatory Agency

NCE New Chemical Entity

NPC National Pharmacovigilance Center

RA Regulatory Affairs

SDR Saudi Drug Registration system

SFDA Saudi Food and Drug Authority

Swissmedic Swiss Agency for Therapeutic Products

TGA Therapeutic Goods Administration

TSE Transmissible Spongiform Encephalopathy

US FDA United States of America Food and Drug Administration

9

Glossary

Applicant The company or its representative

Biologicals

Medicinal products derived from a variety of natural

sources such as human or animal tissues, or microbiological

origins and produced by Culture & purification techniques.

They include a wide range of products such as vaccines,

blood and blood components, allergenics, somatic cells,

gene therapy, and tissues

Biosimilars

Therapeutic proteins produced by recombinant DNA

technology or gene expression method following the

footsteps of one licensed reference biotechnological

product after the expiration of the innovator’s patent. They

are complex and heterogeneous in their nature; hence they

are not considered generics, but as closely similar to the

innovator’s drug as possible

Biotechnology

products

Medicinal products produced by biotechnology methods

and other cutting-edge technologies. They include a wide

range of products such as recombinant Blood products,

recombinant vaccines, and Biosimilars

Blood products

They are a wide range of medicinal product sourced from

human blood or plasma (source material) that can be

collected and tested at “Blood Establishments” and

obtained by industrial process “Fractionation” of human

plasma of a large number of donations (up to tens of

thousands) that are pooled together

Validation (Business

& technical)

The process of checking if documents satisfy a certain

criterion

Common Technical

Document (CTD)

An international harmonized format for submissions for

approval of pharmaceuticals. The CTD provides a

standardization of the presentation of the content

Dosage form

The finished formulation of a pharmaceutical product, e.g.

tablet, capsule, suspension, solution for injection,

suppository

Drug

An article intended for use in the diagnosis, cure mitigation,

treatment, or prevention of disease and which is intended to

affect the structure or function of the body

10

Drug Application A drug application includes the application form, the

product file and the drug samples

Generic

(multisource)

product

A product created to be equivalent to the innovative / brand

name product in dosage form, strength, route of

administration, quality, performance characteristics and

therapeutic indication(s)

Note:

Drug application will be considered as Generic irrespective

of whether the innovative product registered or not at

SFDA

Hard copy - product

file

The paper-based submission of selected documents of the

product file

Health product Refer to the SFDA classification guidance

Herbal product

Any finished labeled medicinal products that contain as

active ingredients aerial or underground parts of plants or

other plant materials or the combination of them, whether

in crude state or plant preparation that is used to treat or

prevent diseases or ailments or to promote health and

healing. Plant materials include juices, gums, fatty oils and

any other substance of this nature

New (innovative)

product

A product that includes new chemical entity and launched

in the market by the innovator company

Inquiry A questions or clarifications posted in SDR system to be

responded by the applicant

Medicinal gas Any gas or mixture of gases classified as a medicinal

product

Radiopharmaceutical

product

A radioactive drug that can be administered safely to

humans for diagnostic and therapeutic purposes.

Reference number /

sub-product number

Any combination of letters and numbers that is assigned to

the transaction in order to follow it.

Renewal of

marketing

authorization

A process of renewing the marketing authorization license

every five years.

SADAD A system that links between the commercial sector and the

local banks; it offers the ability to collect its customer

11

payment electronically through all the banking channels in

KSA around the clock.

SFDA's pricing rules

The pricing guideline “The Rules for Pharmaceutical

Products Pricing” which include the general requirements

and criteria for pricing a pharmaceutical product and

constitute the general framework of the “Pharmaceutical

Products Pricing Committee” to suggest the price.

Product file The electronic version of the product file presented in CDs

or DVDs.

Stringent Regulatory

Authority (SRA)

For human products: USFDA, EMA, MHRA,

Swissmedic, Health Canada and TGA.

For veterinary products: European Medicine Agency

(Europe), Veterinary Medicines Directorate (UK), Health

Canada Drug Product Database (Canada), Australian

Pesticides and Veterinary Medicines Authority (Australia),

Food and Drug Administration (USA), The French Agency

for Veterinary Medicinal Products (France), Health Product

Regulatory Authority (Ireland), Federal Office of

Consumer protection and Food Safety & Paul Ehrlich

Institute (Germany), New Zealand Food Safety (New

Zealand), Federal Agency for Medicines and Health

Products (Belgium), The Netherlands Veterinary

Medicines Institute (Netherlands) and Spanish Agency of

Medicines and Medical Devices (Spain).

Vaccines

Preparations that contain antigenic substances capable of

inducing a specific and active immunity against the

infecting agent or the toxin or the antigen produced by it.

Variation A process of informing SFDA of any minor or major

changes in the drug product.

Veterinary product

Any substance or combination of substances presented as

having properties for treating or preventing disease in

animals; or any substance or combination of substances that

may be used in, or administered to, animals with a view

either to restoring, correcting or modifying physiological

functions by exerting a pharmacological, immunological or

metabolic action, or to making a medical diagnosis.

Wave Set of inquiries from one or multiple departments sent to

applicants during assessment process.

12

1. INTRODUCTION

The Drug Sector in the Saudi Food & Drug Authority (SFDA) has developed this

administrative document to provide assistance for stakeholders on how to submit

applications for various types of drug products and the procedure to authorize the

applications.

Besides the Market Authorization Application (MAA) of various types of drug

products, it also describes variations applications and renewal of MAA. Various

application forms and time-frame for processing applications to marketing the

product in Saudi Arabia are also included in this document.

2. Scope:

This framework applicable to all types of drug product submitted for registration,

variation or renewal.

13

3. NEW MARKETING AUTHORIZATION APPLICATION

(MAA) 1

The MAA of pharmaceutical product will be subjected to the followings processes:

3.1. Submission

The process of submitting a New MAA consists of two steps:

3.1.1. Online submission

1. The applicant shall apply through SDR system to fill the application

form and pay the fees

2. Upload the product file; The components of the file shall follow the

requirements and guidelines published on SFDA website

3.1.2. Validation

The product file will be validated in technical and business bases to

ensure the applicant fulfills the requirement. The validation involves two

steps:

3.1.2.1. Technical validation

The SDR system will validate the submission automatically after the

company upload the file on the SDR portal. The validation’s result will

be sent by email through SDR system to the applicant.

3.1.2.2. Business validation

1. The product file will be validated to ensure that all information

provided is according to the requirements and guidelines.

2. If any information is missing or incorrect, an electronic inquiry

will be forwarded to the applicant through the SDR system. The

applicant will be given an opportunity to complete the file within

30 working days.

1 Performance targets for every step provided at the end of this part (section 3.5) for all pathways

(Regular, priority, verification and abridged)

14

3. The completed file will proceed to the next steps for Assessment

(section 3.2)

The registration request will be rejected in the following cases:

No response from the applicant within 30 working days.

Failure to provide acceptable clarifications after the 4th wave.

Figure 1 Schematic chart of the submission process (section 3.1)

3.2. Assessment

The MAA for different drug submission types subject to the following

processes:

3.2.1. Evaluation / Inspection

1. The RA will distribute the registration request to the relevant related

departments to assess quality, safety and efficacy.

For Inspection: the department will check the approval of

manufacturing line; if not approved:

15

o Visit will be scheduled for inspection depending on

the time available for both inspectors and the

company.

o After the visit, the inspection report will be sent to the

company (please, refer to the guidance of Good

Manufacturing Practice for Medicinal product).

2. If more information or clarification is required, an electronic inquiry will

be posted through SDR system as one wave for evaluation and

inspection. A response should be received within 90 working days.

3. Once the evaluation and inspection are completed, the registration

request will be forwarded to Pricing (section 3.3)




3.2.2. Testing:

1. The registration request will be forwarded to the SFDA Central

Laboratories.

2. If more information or clarification is required, an electronic inquiry

will be posted through SDR system

3. Samples and working standards shall be delivered by the applicant to

SFDA Central Laboratories.

Notes:

Testing will not delay the registration of a product.

The first batch will not be released if the company did not submit the

requirements and inquiries that requested by SFDA Central

Laboratories during product registration period.

16

3.3. Pricing

1. The Pricing Department will review product’s price according to the

“SFDA's pricing rules”.


be posted through SDR system. A response should be received within 90

working days.

3. The product’s price will be forwarded to Registration Committee

(section 3.4).




3.4. Product licensing

1. The Registration Committee will review the registration request for

approval, rejection or ask for further information (if needed).

2. The SFDA CEO will approve the meeting minutes.

3. For approved registration request, the applicant will be notified through

SDR system to issue the MA. Otherwise, submit an appeal.

Appeal Process:

The applicant has the right to appeal against any decision within 60 calendar days,

for more information refer to Guidance for Submission.

17

Figure 2 schematic figure showing the different levels for getting a marketing authorization

(section 3.2, 3.3 and 3.4)

18

3.5. Registration performance targets

The performance target in any step will STOP if a clarification or

information is needed from the applicant, and resume after receiving the

response.

All days are considered as working days.

Total Performance Target calculated without the Business Validation for

all pathways

2 For Evaluation 3 For inspection

3.5.1. Regular pathway:

Registration

phases

Technical

Validation

Business

Validation

Evaluation /

Inspection

Testing Pricing Product

licensing

Total

Performance

Target section

3.1.2.1

section

3.1.2.2

section

3.2.1

section

3.2.2

section

3.3

section

3.4

No. of Waves - 4 4 - 4 -

Human Generic - 10 120 - 20 15 155

Human New Drugs

registered in SRA

- 10 245 - 20 15 280

Human New Drugs not

registered in SRA

- 10

370

- 20

15

405

Human Biologics

registered in SRA

- 10

245

- 20

15

280

Human Biologics not

registered in SRA

- 10

370

- 20

15

405

Radiopharmaceuticals - 10

245

- 20

15

280

Veterinary Generics - 10

150

- - 15

165

Veterinary New Drugs

registered in SRA

- 10

245

- - 15

260

Veterinary New Drugs

not registered in SRA

- 10

370

- - 15

385

Veterinary Biologics

registered in SRA

- 10

245

- - 15

260

Veterinary Biologics not

registered in SRA

- 10

370

- - 15

385

Herbal & health

products

- 10

602

303

- 20

15

95

19

3.5.2. Priority review pathway (40% reduction)4:

3.5.3. Verification & abridged pathway5:

4 Refer to the Guidance for Priority Review of Product Registration 5 Refer to the Registration According to Verification and Abridged

Registration

phases

Technical

Validation

Business

Validation

Evaluation

/

Inspection


licensing

Total

Performance

target

section

3.1.2.1

section

3.1.2.2

section

3.2.1

section

3.2.2

section 3.3 section

3.4

No. of Waves - 4 4 - 4 -

Human Generic - 10 72 - 12 9 93

Human New Drugs

registered in SRA

- 10

147 - 12 9 168

Human New Drugs

not registered in SRA

- 10

222

- 12 9 243

Human Biologics

registered in SRA

- 10

147 - 12 9 168

Human Biologics not

registered in SRA

- 10

222 - 12 9 243

Radiopharmaceuticals - 10 147 - 12 9 168

Registration

phases

Technical

validation

Business

validation

Evaluation /

Inspection


licensing

Total

Performance

target

section

3.1.2.1

section

3.1.2.2

section

3.2.1

section

3.2.2

section

3.3

section

3.4

No. of Waves - 4 4 - 4 -

Verification - 5 15 - 5 10 30

Abridged - 5 40 - 10 10 60

20

4. VARIATION OF MARKETING AUTHORIZATION6

Any changes on a registered product has to be submitted to the SFDA as a Variation

of MAA. The variations are classified into two main categories:

A. Minor changes

Type IA: minor variations that does not require prior approval before

implementation (“Do and Tell” procedure) but require notification

submitted by MAH within 60 working days after implementation.

Type IB: minor variations that must be submitted to the SFDA by MAH

before implementation, but do not require a formal approval. However,

the MAH must wait a period of 60 working days to ensure that the

application is deemed acceptable by the SFDA before implementing the

change (“Tell, Wait and Do” procedure).

B. Major variation

Type II: major variations in which there might be a significant impact

on the Quality, Safety or Efficacy of a pharmaceutical product and

require prior approval before implementation.

The variation request subjects to the following process:

4.1. Submission

The process of submitting a variation of MAA consists of two steps:

4.1.1. Online submission


form and pay the fees.

2. Upload the product file; The components of the file shall follow the

requirements and guidelines published on SFDA website

For applications made via the new SDR system, three parallel variation

applications can be submitted at a time, each includes administrative, quality

or safety variations. Each category of variations will be assigned to the

related departments.

6 Performance targets for each step provided at the end of this part (section 4.5)

21

4.1.2. Business Validation


provided is according to the requirements and/or guidelines.

2. If any information is missing or incorrect, an electronic inquiry

will be forwarded to the applicant through the SDR system. The

applicant will be given an opportunity to complete the file within

30 working days.

3. The completed file will proceed to the next step for Assessment

(section 4.2).

The variation request will be rejected in the following cases:


Failure to provide acceptable clarifications after the first wave.

4.2. Assessment

Depending on the type of variation, one or more department may review the

variation application.

4.2.1. Evaluation / Inspection:

1. The variation request will be distributed to the relevant related

department – as needed;

For the inspection related requests: the department will check

the approval of manufacturing line, If not approved:

o Visit will be scheduled for inspection depending on

the time available for both inspectors and the

company.

o After the visit, the inspection report will be sent to the

company (please, refer to the guidance of Good

Manufacturing Practice for Medicinal product).


be posted through SDR system. The response should be received within

90 working days.

22

3. Reports (recommendation for approval or rejection) will be collected by

the RA.

4. The reports will be forwarded (if needed) to pricing (section 4.3) and

registration committee (section 4.4) depending on the type of variation.




4.3. Pricing

1. The Pricing Department handles all variation requests that require

pricing review according to “SFDA’s pricing rules”.

2. If more information or clarification is required, an electronic Inquiry will

be posted through SDR system. A response should be received within 90

working days.

3. The approved price will be forwarded to the Registration Committee

(section 4.4).




4.4. Product Licensing

For all variation types except variation affecting product price:

1. The RA will approve the final report.

2. Notify the applicant through SDR system.

For variation affecting product price:

1. The Registration Committee will review the variation request for

approval, rejection or ask for further information (if needed).

23

2. The SFDA CEO will approve the meeting minutes.

3. For approved variation request, the applicant will be notified

through SDR system. Otherwise, submit an appeal.

General variation notes:

For applications made via the new SDR system; after the completion of an

application of a particular category (by approval or rejection), another

application of the same category can be submitted.

For application includes more than one type of variation, the maximum total

performance target will be considered. For example: application includes

type 1B and type II, the total performance target for the application is 100

working days.

Appeal Process:

The applicant has the right to appeal within 60 calendar days of the SFDA’s final

decision, for more information refer to Guidance for submission.

Figure 3 Schematic figure showing the workflow of Variation

24

4.5. Variation performance targets:

The performance target in any step will STOP if a clarification or

information is needed from the applicant, and resume after receiving the

response.

All days below are considered as working days.

Total Performance Target calculated without the Business Validation for

all types of variations.

Phases

Business

Validation

Assessment Pricing Product

licensing

Total Performance

target section 4.1.2 section 4.2 section 4.3 section 4.4

No. of Waves 1 1 1 -

Type IA 5 20 - 10 30

Type IB 5 40 10 10 60

Type II 5 80 10 10 100

5. RENEWAL OF MARKETING AUTHORIZATION7

An applicant shall submit a renewal request every five years. It is possible to request for

renewal within six months of the certificate expiry.

As most of the registered drugs have went through at least one renewal process or have

been registered through SDR system; therefore, the renewal process is shorter as follows:

5.1. Submission

The process of submitting a renewal of MA consists of two steps:

5.1.1. Online submission:


form and pay the fees.

2. Upload the renewal file; The components of the file shall follow the

requirements and guidelines published on SFDA website.

5.1.2. Business Validation:


provided are according to the requirements and/or guidelines.

2. If any information is missing or incorrect, an electronic Inquiry will

be forwarded to the applicant through SDR system. The applicant will

be given an opportunity to complete the file within 30 working days.

3. The completed file will proceed to the Pricing Department (section

5.2).

The renewal request will be rejected in the following cases:



7 Performance targets for each step provided at the end of this part (section 5.4)

26

5.2. Pricing

1. The Pricing Department will review the price according to the “SFDA's

pricing rules”.

2. If more information or clarification is required, an electronic inquiry will be

posted through SDR system. A response should be received within 30

working days.

3. The approved price will be forwarded to the product licensing (section 5.3).

The renewal request will be rejected in the following cases:



5.3. Product Licensing

1. The RA will issue the renewal of MA.

2. The applicant will be notified through SDR system. Otherwise, submit an

appeal.

Note: The rejected renewal applications obligate the applicant to submit a new one.

Figure 4 Schematic figure showing the renewal process of a marketing authorization

27

5.4. Renewal performance targets:

The performance target in any step will STOP if a clarification or information

is needed from the applicant, and resume after receiving the response.

All days below are considered as working days.

Total Performance Target calculated without the Business Validation.

Phases of Renewal No. of Waves Total Performance target

Business validation

(section 5.1.2)

1 5

Pricing

(section 5.2)

1 30

Product licensing

(section 5.3)

- 10

Total performance target: 40

28

6. APPENDIX

6.1. Application Forms

Application form Page

Marketing Authorization Application of Pharmaceutical Product 30

Application for Variation to a Marketing Authorization 61

Note:

The application forms are available electronically in SDR system. These forms

are only for viewing and preparing the required information before starting the

process of submission.

29

تسويق مستحضر دوائيطلب رخصة

Marketing Authorization Application for Pharmaceutical Product

30

1 Type of Application

The following sections should be completed where appropriate.

This application concerns:

Human medicinal product

Herbal product

Veterinary product

1.1 Please choose the type of product:

Human medicinal product

New Drug (1.2.1.1)

Biological Drug (1.2.1.2)

Radiopharmaceutical Drug (1.2.1.3)

Generic (Multisource) Drug (1.2.1.4)

Health product (1.2.1.5)

Veterinary product

New Drug (1.2.3.1)

Biological Drug (1.2.3.2)

Generic (Multisource) Drug (1.2.3.3)

Health product (1.2.3.4)

Herbal product (1.2.3.5)

1.2 Please provide the following information for the product:

1.2.1 Human medicinal product

1.2.1.1 New Drug Application

New Chemical Entity (NCE)

Known active substance

31

1.2.1.1.1 Is Saudi Arabia the country of origin (COO)?

Yes (go to section 2)

No (complete the following information)

Product information in COO:

Trade name:

Product strength/unit:

Dosage form:

Marketing Authorization holder:

o Name:

o Address :

Line 1:

Line 2:

Line 3:

Postal/Zip code:

City:

Country:

o Certifying Authority:

o Date of authorization (dd/mm/yyyy):

o Country:

1.2.1.1.2 Is the product registered in GCC?

Yes, please specify the following

o Registration number:

o Trade name:

o Committee meeting number:

No

1.2.1.1.3 Is this product registered in SRA?

Yes, please specify the SRA:

32

No

1.2.1.1.4 Is this product under-license?

Yes, please specify the MAH:

No

1.2.1.1.5 Is this product from the SFDA exemption list?

Yes, please choose the product:

No

1.2.1.1.6 This product is candidate for:

Abridge registration process

Verification registration process

Priority review process, please specify the SFDA letter number:

None of the above

1.2.1.2 Biological Drug Application

Biological

Biosimilar

Blood product

Vaccine

Others, please specify:





Trade name:


Dosage form:

Marketing authorization holder:

33

o Name:

o Address :

Line 1:

Line 2:

Line 3:

Postal/Zip code:

City:

Country:

Certifying Authority:

Date of authorization (dd/mm/yyyy):

Country:




o Trade name:


No



No



No



No



34



None of the above

1.2.1.3 Radiopharmaceutical Drug Application

1.2.1.3.1 Is Saudi Arabia the country of origin(COO)?




Trade name:


Dosage form:

Marketing authorization holder information in COO:

o Name:

o Address :

Line 1:

Line 2:

Line 3:

Postal/Zip code:

City:

Country:



o Country:




o Trade name:


35

No



No



No



No





None of the above

1.2.1.4 Generic (Multisource) Drug Application


Yes (complete part 1.2.1.4.2)

No (complete the following information):

Product information:

Trade name:


Dosage form:


o Name:

o Address :

Line 1:

36

Line 2:

Line 3:

Postal/Zip code:

City:

Country:



o Country:

1.2.1.4.2 Reference Product Information:

Trade name:


Dosage form:




o Trade name:


No

1.2.1.4.4 Is the product a 1st or 2nd Generic?

Yes, please choose:

1st Generic

2nd Generic

No

1.2.1.4.5 Is this product a 2nd Brand?

Yes, please choose the Innovator product from the list:

No



37

No



No

1.2.1.4.8 Is this product candidate for Priority Review process?

Yes, please specify the SFDA letter number:

No

1.2.1.5 Health product Application


Yes (complete section 2)



Trade name:


Dosage form:


o Name:

o Address :

Line 1:

Line 2:

Line 3:

Postal/Zip code:

City:

Country:



o Country:

38



No

1.2.2 Herbal product

Is Saudi Arabia the country of origin(COO)?




Trade name:


Dosage form:

Marketing authorization holder information in COO:

o Name:

o Address :

Line 1:

Line 2:

Line 3:

Postal/Zip code:

City:

Country:



o Country:



No

39

1.2.3 Veterinary product

1.2.3.1 New Drug Application

New Chemical Entity (NCE)

Known active substance





Trade name:


Dosage form:


o Name:

o Address :

Line 1:

Line 2:

Line 3:

Postal/Zip code:

City:

Country:



o Country:




o Trade name:


40

No



No



No



No





None of the above

1.2.3.2 Biological Drug Application

Biological

Biosimilar

Blood product

Vaccine

Others (please specify):

Is Saudi Arabia the country of origin (COO)?




Trade name:


41

Dosage form:

Marketing authorization holder:

o Name:

o Address :

Line 1:

Line 2:

Line 3:

Postal/Zip code:

City:

Country:

Certifying Authority:

Date of authorization (dd/mm/yyyy):

Country:




o Trade name:


No



No



No



No

42





None of the above

1.2.3.3 Generic (Multisource) Drug Application


Yes (complete part 1.3.3.3.2)



Trade name:


Dosage form:


o Name:

o Address :

Line 1:

Line 2:

Line 3:

Postal/Zip code:

City:

Country:



o Country:

1.2.3.3.2 Reference Product Information:

Trade name:

43


Dosage form:




o Trade name:


No

1.2.3.3.4 Is the product a 1st or 2nd Generic?

Yes, please choose:

1st Generic

2nd Generic

No

1.2.3.3.5 Is this product a 2nd Brand?

Yes, please choose the Innovator product from the list:

No



No



No

1.2.3.3.8 Is this product candidate for Priority Review process?

Yes, please specify the SFDA letter number:

No

1.2.3.4 Health product Application


44




Trade name:


Dosage form:


o Name:

o Address :

Line 1:

Line 2:

Line 3:

Postal/Zip code:

City:

Country:



o Country:



No

1.2.3.5 Herbal product Application





Trade name:

45


Dosage form:


o Name:

o Address :

Line 1:

Line 2:

Line 3:

Postal/Zip code:

City:

Country:



o Country:



No

46

2 Product Information Details


2.1 Product information:

2.1.1 Proposed trade name in English:

2.1.2 Proposed trade name in Arabic:

2.1.3 Product number 1:

2.1.3.1 List the active substance(s):

Single active substance

Multiple active substances

Name of

active

substance(s)

Operator8 Quantity Unit

Reference/

Monograph

standard

2.1.3.2 List the excipient(s):

Name of

excipient(s) Operator1 Quantity Unit

Reference/

Monograph

standard

2.1.3.3 Pharmaco-therapeutic group: (Please use current ATC code)

ATC Code Group

No ATC code has been assigned

2.1.3.4 Raw plant materials: (for Herbal products only)

8 Quantity operator: equal to, less than, more than, less than or equal to, more than or equal to, equivalent to, approximately equal to, range

47

2.1.3.5 Scientific name, family: (for Herbal products only)

2.1.3.6 Traditional or common name (Arabic and/or English): (for Herbal

products only)

2.1.3.7 Used parts: (for Herbal products only)

2.1.3.8 Dosage form:

2.1.3.9 Strength

2.1.3.10 Unit of strength:

2.1.3.11 Package size: 1 value only

Package size Volume Unit of Volume

2.1.3.12 Route of administration:

2.1.3.13 Administration device (if applicable):

2.1.3.14 Primary packaging:

2.1.3.15 Secondary packaging:

2.1.3.16 Is a GTIN assigned for this pack?

Yes, please specify the value:

No

2.1.3.17 Proposed shelf life:

2.1.3.18 Proposed shelf life after first opening (if applicable):

2.1.3.19 Proposed shelf life after reconstitution or dilution (if applicable):

2.1.3.20 Proposed storage conditions:

2.1.3.21 Proposed storage conditions after first opening (if applicable):

2.1.3.22 Reference Pharmacopoeia:

2.1.3.23 Do you have a Certificate of a Pharmaceutical Product (CPP)?

Yes

No

48

If not, do you have a marketing authorization (or free sales) certificate

from the country of origin (COO)?

Yes

No

2.1.3.24 List and specify any material of animal source contained in any

component of the product, if applicable:

Material Animal Animal part Free from BSE/TSE

Please note that any pork content has to be clearly specified.

It should be noted that all material used must be free from BSE/TSE. If a certificate confirming that the product is free from BSE/TSE is available, it should be provided.

2.1.3.25 Maximum Residual Limit (MRL) Status: (only for food producing

species)

Substance(s) Species Target tissue(s) MRL Remarks

2.1.3.26 Withdrawal Period:

2.1.3.27 Withdrawal Period Unit:

49

3 Manufacturers Details:


3.1 Active Pharmaceutical Ingredient (API) manufacturers:

Name of manufacturer

Name of ingredient

Address9 Phone Fax Activity

10

Is it GMP certified?

Yes No

Certifying Authority

Date of certification

(dd/mm/yyyy)

3.2 Excipients manufacturers:

Name of

manufacturer

Name of

excipient Address3 Phone Fax Activity3

Is it GMP

certified?

Yes No

Certifying

Authority

Date of

certification

(dd/mm/yyyy)

3.3 Finished Product manufacturers:

Name of manufacturer

Address3 Phone Fax Activity3 Is it GMP certified?

Yes No

Certifying Authority

Date of certification

(dd/mm/yyyy)

9 Full address as Line 1, 2 & 3; Postal/Zip code, City & Country 10 A drop-down menu

50

4 Marketing Authorization Details


4.1 Marketing authorization holder legally responsible for placing the

product on the market in KSA11:

Company Name:

Address:

o Line 1:

o Line 2:

o Line 3:

o Postal/Zip code:

o City:

o Country:

Phone:

Fax:

E-Mail:

4.2 Person authorized for communication in KSA on behalf of the

applicant:

Person Name:

o First name:

o Middle name:

o Family/last name:

Company Name12:

Address:

11 A drop-down menu (transferred from DENR or Re-engineered system after normalization) 12 A drop-down menu (transferred from DENR or Re-engineered system after normalization)

51

o Line 1:

o Line 2:

o Line 3:

o Postal/Zip code:

o City:

o Country:

Phone:

Fax:

E-Mail:

4.3 Person/Company authorized for communication between the

marketing authorization holder and the SFDA after authorization, if

different from 3.2 in KSA:

Person Name:

o First name:

o Middle name:

o Family/last name:

Company Name13:

Address:

o Line 1:

o Line 2:

o Line 3:

o Postal/Zip code:

o City:

o Country:

Phone:

13 A drop-down menu (transferred from DENR or Re-engineered system after normalization)

52

Fax:

E-Mail:

4.4 Person qualified for Pharmacovigilance in KSA:

Name:

o First name:

o Middle name:

o Family/last name:

Address:

o Line 1:

o Line 2:

o Line 3:

o Postal/Zip code:

o City:

o Country:

Phone:

Fax:

E-Mail:

53

5 Scientific Advice

5.1 Was there any formal scientific advice given by the SFDA for this

medicinal product?

Yes, please complete the following:

Date (dd/mm/yyyy):

Reference number of the scientific advice letter:

No

54

6 Pediatric Development Program

6.1 Is there a pediatric development program for this medicinal product?

Yes, please indicate the relevant section(s) in the dossier:

No

55

7 Legal Status of the Product


7.1 Proposed dispensing classification:

Subject to medical prescription:

By a licensed doctor in the KSA:

Consultant

Senior Assistant

Assistant

GP

Restricted prescription

Special distribution program

Hospital-only item

Not subject to medical prescription:

By a licensed Pharmacist – Behind the counter (BTC)

Over the counter (OTC)

56

8 Status of the application in other regulatory agencies

Tick the appropriate box and fill the information.

Authorized

List all countries where the product is authorized for marketing:

Country Trade name

Product strength/unit

Dosage form

Marketing authorization

holder

Date of authorization (dd/mm/yyyy)

Pending

List all countries where the product application is pending:

Country Trade name


Dosage form

Date of submission

(dd/mm/yyyy)

Refused

List all countries where the product has been refused for marketing:

Country Trade name


Dosage form

Reason for refusal

Date of refusal (dd/mm/yyyy)

Withdrawn (by applicant after authorization)

List all countries where the product has been withdrawn after authorization:

Country Trade name


Dosage form

Date of withdrawal

(dd/mm/yyyy)

Reason for withdrawal

Suspended/revoked (by competent authority)

List all countries where the product has been suspended or revoked:

Country Trade name


Dosage form

Date of suspension/rev

Reason for suspension/ revocation:

57

ocation (dd/mm/yyyy)

9 Price Certificate Form


9.1 Ex-Factory Price:

9.1.1 Country of Origin’s currency

9.2 Wholesale Price


9.3 Public price


9.4 Proposed CIF to KSA

9.4.1 Currency

9.5 The other price in countries where the product is marketed:

No

Countr

y

Nam

e

Pack S

ize

Ex-

Facto

ry

Price

Curr

ency

CIF

Price

Curr

ency

Pub

lic

price

Curr

ency

note

s

1 Algeria

2 Australia

3 Argentina

4 Bahrain

5 Belgium

6 Canada

7 Cyprus

8 Denmark

9 Egypt

10 France

58

No

Countr

y

Nam

e

Pack S

ize

Ex-

Facto

ry

Price

Curr

ency

CIF

Price

Curr

ency

Pub

lic

price

Curr

ency

note

s

11 Germany

12 Greece

13 Holland

14 Hungary

15 Ireland

16 Italy

17 Jordan

18 Kuwait

19 New Zealand

20 Oman

21 Portugal

22 Lebanon

23 Japan

24 South Korea

25 Spain

26 Sweden

27 Switzerland

28 Turkey

29 UAE

30 UK

31 Others

59

Declaration:

I hereby certify that the submitted information is true and accurate and changes

will not be made until they are approved by SFDA.

Title:

Name:

Signature:

Date:

Company stamp:

60

ة التسويق طلب تعديل رخص

Application for Variation to a Marketing Authorization

61

1 Request type

1.1 This application concerns:

Administrative Changes

Quality Changes

Safety, Efficacy, or Pharmacovigilance Changes

62

2 Type(s) of variation(s):

2.1 Variations included in this application:

Number and title of

variation, as per the

guideline14

Procedure Type Date of

Implementation

2.2 Precise scope and background for change (Include a description

and background of all the proposed changes with its proposed

Classification)

Current Proposed

2.3 Does this change affect the last updated drug application form?

Yes, which part? Please specify to the lowest level and state the new

value:

Section 2 - Product Information Details: Please choose the

field(s) and type the new value

Section 3 - Manufacturers Details: Please choose the field(s)

and type the new value

Section 4 - Marketing Authorization Details: Please choose the


14 Choose from the drop-down menu of all variations in the GCC variation guideline

63

Section 7 - Legal Status of the Product: Please choose the


Section 9 - Price Certificate Form: Please choose the field(s)

and type the new value

No

Declaration:

I hereby certify that the submitted information is true and accurate and changes

will not be made until they are approved by SFDA.

Title:

Name:

Signature:

Date:

Company stamp:

64

Documents

New Regulatory Framework for Drug Approvals - SFDA · 2020. 3. 23. · 2.0 Licensing department 15 July 2008 Published for comments 3.0 Licensing department 19 January 2009 Revised